Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
Alnylam's (ALNY) Q1 Loss Narrower Than Expected, Revenues Beat
12:01pm, Friday, 30'th Apr 2021
Alnylam (ALNY) beat estimates for both earnings and revenues in the first quarter of 2021.
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q1 2021 Results - Earnings Call Transcript
03:12pm, Thursday, 29'th Apr 2021
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q1 2021 Results - Earnings Call Transcript
Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
02:00pm, Monday, 19'th Apr 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced full positive results from the HELIOS-A Phase 3 study of vutrisi
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive interim results from the ongoing Phase 1 study of ALN-A
Alnylam, Vir Biotech Deprioritize COVID-19 Drug Development In Hushed Manner
11:47am, Wednesday, 17'th Mar 2021
Last week, Vir Biotechnology Inc's (NASDAQ: VIR) and its collaborating partner GlaxoSmithKline Plc (NYSE: GSK) announced interim Phase 3 data from COVID-19 antibody therapy, named VIR-7831 (GS
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
04:00pm, Monday, 22'nd Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following
Delta Air, Foot Locker, Nvidia, Petrobras and More Monday Afternoon Analyst Calls
12:46pm, Monday, 22'nd Feb 2021
With the trading day more than halfway over, the broad markets could not make up their mind on a direction.
Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q4 2020 Results - Earnings Call Transcript
03:27pm, Thursday, 11'th Feb 2021
Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q4 2020 Results - Earnings Call Transcript
Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates
10:35am, Thursday, 11'th Feb 2021
Alnylam (ALNY) delivered earnings and revenue surprises of -8.29% and 14.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Alnylam Pharmaceuticals Q4 Earnings
09:55am, Thursday, 11'th Feb 2021
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 19.19% over the past year to ($1.60), which beat th
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new 5-year strategy “Alnylam P5x25” focused on the Compa
Alnylam Pharmaceuticals Logs Another Clinical Win For Its Amyloidosis Program
06:07pm, Friday, 08'th Jan 2021
Alnylam announced that the HELIOS-A Phase III study of vutrisiran for hATTR-polyneuropathy achieved all of its primary and secondary endpoints. Vutrisiran's improved dosing profile and tolerability ar
Alnylam (ALNY) Posts Positive Top-Line Data From Vutrisiran Study
10:32am, Friday, 08'th Jan 2021
Alnylam (ALNY) reports positive top-line results from the phase III -HELIOS-A study of vutrisiran in development for the treatment of transthyretin-mediated amyloidosis with polyneuropathy.
Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference
04:00pm, Monday, 04'th Jan 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 39th Annu
Alnylam Appoints Tolga Tanguler Chief Commercial Officer and Also Announces New CEMEA, Medical Affairs, and Compliance Leaders
08:00am, Monday, 21'st Dec 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of Tolga Tanguler to the role of Chief Commercia
